Atomoxetine & Propranolol

Small molecule

Atomoxetine & Propranolol is one of 22 small molecule programs targeting Orthostatic Intolerance. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic IntoleranceActive, not recruiting

Orthostatic IntolerancePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Orthostatic Intolerance

#DrugCompanyPhaseTrials

Northera

Corlanor

Giapreza

LLa Jolla Pharmaceutical Company

Prometrium

Medrol

1 6

Isotonic Sodium Chloride

Eli Lilly

Phase 3

1 7

Namenda

AbbVie

Phase 2

1 8

Isordil

AstraZeneca

Phase 2

1 9

Diamox

Teva

Phase 2

1 10

Comtan

Orion Corporation, Orion Pharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Active, not recruiting

Orthostatic Intolerance

NCT00262470

Clinical

Trials by Indication[1]

Orthostatic Intolerance1 trial

Treatment of Orthostatic Intolerance

Active, not recruiting·SSatish R. Raj·Phase 1/2·NCT00262470·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atomoxetine & Propranolol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atomoxetine & Propranolol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atomoxetine & Propranolol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Satish R. Raj company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSatish R. Raj

Atomoxetine & Propranolol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Orthostatic Intolerance1 trial

References

Drug Info

Quick Facts

Related News